Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 11/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270261 | 0.85 | CYP2C9 (0.46) | TDP1DCAF1MEN1GFERKMT2A | |
| SCHEMBL1672584 | 0.81 | TDP1 (0.63) | ACLYTDP1DHODHDCAF1KDM5B | |
| SCHEMBL27696872 | 0.78 | HSP90AA1 (0.62) | TDP1DCAF1HSP90AA1HSP90AB1MEN1 | |
| SCHEMBL28059476 | 0.78 | LMNA (0.51) | DCAF1KDM5B | |
| SCHEMBL2268189 | 0.78 | ACLY (0.61) | ACLYDHODHSUCNR1HDAC1 | |
| SCHEMBL1320352 | 0.77 | ACMSD (0.68) | ACLYDHODHMEN1GFERKMT2A | |
| SCHEMBL2270222 | 0.77 | DHODH (0.77) | ACLYTDP1DHODHMEN1KMT2A | |
| SCHEMBL2275453 | 0.77 | ACLY (0.76) | ACLYTDP1DHODHMEN1KMT2A | |
| SCHEMBL1317052 | 0.76 | ACLY (0.64) | ACLYDHODHMEN1KMT2ASUCNR1 | |
| SCHEMBL2275016 | 0.76 | TP53 (0.58) | ACLYTDP1DHODHHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885TDP1 3823/4885DHODH 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.